'Next Generation' Drug Development Strategies

By David Cameron, Senior Director & Global Head, Novel Trial Design, IQVIA and Lucas Glass, Vice President of Artificial Intelligence, IQVIA

Asia Pacific’s biotech companies are increasingly challenged to stay agile in their drug development process while ensuring patient centricity. Innovative trial design is an important strategy for these companies to stay ahead. From screening master protocols to the use of data science and artificial intelligence (AI), how can biotech companies achieve the best patient outcomes? Here are three considerations for companies when planning drug development strategies.